Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia

IgNova

Status: Completed

Conditions: Fibromyalgia; Chronic Widespread Pain

Treatments: Drug: Parol 500 mg Tablets (acetaminophen); Drug: IGN-ES001

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03058224

IGN-ES001-CR01

Details and patient eligibility

About

This is a randomized, double-blind, placebo-controlled exploratory trial to investigate efficacy and safety of food supplement IGN-ES001 in patients with chronic widespread pain (CWP) with or without fibromyalgia (FM).

Full description

Patients will perform five scheduled on-site visits and five phone calls:

• Screening visit, V1 (Day -10 to -7), informed consent
• Baseline visit, V2 (Day 1), randomization, treatment start
• Phone call, V3 (Day 4 ± 1)
• Phone call, V4 (Day 8 ± 3)
• Phone call, V5 (Day 15 ± 3)
• On-site visit, V6 (Day 22 ± 3)
• Phone call, V7 (Day 29 ± 3)
• Phone call, V8 (Day 36 ± 3)
• On-site visit, V9 (Day 43 + 3), treatment end
• Follow-up on-site visit, V10 (Day 50 + 7, or 7 + 7 days after EDV).

In addition, patients may be asked to return to the trial site between scheduled visits for assessment of safety data (unscheduled visits).

The maximum duration of treatment for the individual patient will be 46 days (including allowed visit window deviation). The maximum duration of trial participation for the individual patient will be 67 days.

Enrollment: 230 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female out-patient ≥ 18 years and ≤ 70 years of age.

2. Patient willing and able (e.g. mental and physical condition) to participate in all aspects of the trial, including use of investigational product, subjective completion of diaries and questionnaires, attending scheduled visits, completing telephone interviews, and compliant with protocol requirements as evidenced by providing signed writteninformed consent.

3. History of chronic widespread pain (for at least three months prior to visit V1 (screening)).

4. a.) For FM patients: Widespread Pain Index (WPI) ≥ 7 and Symptom Severity (SS) ≥ 5 or WPI 3-6 and SS ≥ 9 (original preliminary fibromyalgia criteria of the American College of Rheumatology (ACR) 2010).

   b.) For non-FM CWP patients: WPI ≥ 3-6 and SS ≥ 5-8 (modified from the preliminary fibromyalgia criteria of the ACR 2010).

5. Use of prior and concomitant medications/ therapies (if not excluded, see exclusion criteria no 6 and no 7), non-pharmacological therapies and lifestyle habits (e.g. diet changes, Ramadan participation, etc.) that could influence the efficacy assessments must have been stable for at least 30 days prior to visit V1 (screening) and are anticipated to be at a stable regimen throughout the trial until visit V9.

6. Patient has negative urine test at screening visit V1 for the following drugs of abuse:

   1. Amphetamine
   2. Cocaine
   3. Metamphetamine
   4. Morphine
   5. Tetrahydrocannabinol

7. Female patient is surgically sterile (i.e. bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or at least two years postmenopausal or, if of childbearing potential, she is sexually abstinent or agrees to practice adequate contraceptive measures (hormonal contraceptives, intrauterine device, double-barrier method).

8. Patient must have completed at least 6 screening phase diary pages satisfactorily within the past 7 days before visit V2.

9. Median pain NRS must be ≥ 4 in at least 1 out of the 6 pain qualities and ≥ 4 in overall pain assessment. The median will be calculated from the last 7 days before visit V2 (baseline) and will serve as baseline value.

If all inclusion criteria are fulfilled (and none of the exclusion criteria below), the patient will be randomized at visit V2 and continues in the trial. Otherwise the patient will be excluded from trial participation.

Exclusion criteria

1. Patients without a basic and stable CWP therapy which started at least 30 days before V1 (screening) i.e. treatment-naive patients, first diagnosis.
2. Known allergy or intolerance to egg or egg constituents.
3. History of or currently active malignancy except for malignancies that were successfully treated and have had no recurrence within 5 years before screening visit V1.
4. Known, uncontrolled endocrine disorders, such as hypothyroidism (TSH and free T4), and diabetes mellitus (HbA1c).
5. Known severe hepatic, renal, respiratory, hematologic, neurologic, infectious, or immunologic disease, unstable cardiovascular disease, or any other medical or psychiatric condition that, in the judgment of the investigator, would make the patient inappropriate for participation in this trial.
6. Immune response modulating medication/ therapy e.g. systemic corticosteroids, antibodies other than IP (investigational product) from a period starting 90 days before visit V1 (screening).
7. WHO step-II and step-III opioids (except occasional use of codeine as cough medication) from a period starting 60 days before visit V1 (screening).
8. Intractable vomiting likely to significantly influence gastrointestinal (GI) investigational product presence.
9. Surgery within 60 days before visit V1 (screening) or anticipated or scheduled for the next nine weeks after visit V1 (screening).
10. Vaccination from a period starting 30 days prior to visit V1 (screening).
11. Known liver disease or evidence of impaired hepatic function (total bilirubin, aspartate aminotransferase [ASAT], alanine transaminase [ALAT], gamma-glutamyltransferase [GGT], or alkaline phosphatase [AP] > 3 times the upper limit of normal).
12. Known kidney disease or evidence of impaired renal function, i.e. estimated glomerular filtration rate (eGFR) based on serum creatinine < 60 mL/min as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
13. Pregnancy or breastfeeding.
14. Known severe psychiatric illness (e.g. schizophrenia, major depression, anxiety disorder, obsessive compulsive disorder, panic disorder, social phobia, post-traumatic stress) or personality disorder (e.g. borderline personality). Obvious suicide risk.
15. Current and/ or history of known or suspected drug or substance abuse including alcohol abuse within five years before visit V1 (screening) as stated by the patient and/ or withdrawal symptoms.
16. Previous enrolment in this trial, or participation in any other studies involving investigational products, simultaneously or within six months prior to be screened for this trial (visit V1).
17. Persons committed to an institution by virtue of an order issued either by the judicial or other authorities.
18. Employee of the investigator or trial site, with direct involvement in the proposed trial or other studies under the direction of that investigator or trial site, as well as family members of the employees or the investigators.
19. Patients unable or unwilling to include yoghurt or ayran into their daily diet.
20. Severe diarrhea.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

230 participants in 2 patient groups, including a placebo group

IGN-ES001

Experimental group

Description:

Polyclonal avian immunoglobulin IgY containing specific IgY against E. coli F18ab and S. typhimurium in partially delipidated avian egg yolk powder

Treatment:

Drug: Parol 500 mg Tablets (acetaminophen)

Drug: IGN-ES001

Placebo

Placebo Comparator group

Description:

Polyclonal avian immunoglobulin IgY containing unspecific IgY in partially delipidated avian egg yolk powder

Treatment:

Drug: Parol 500 mg Tablets (acetaminophen)